Antibody recognizing folate receptors α and β
The object of the present invention is to provide an antibody capable of immunologically and specifically binding to a folate receptor α and a folate receptor β. Specifically, the present invention relates to an antibody or a fragment thereof, in which the amino acid sequences of CDRH1, CDRH2, and CDRH3 of a heavy chain variable region (VH) are SEQ ID NOs: 2, 4, and 6, respectively, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of a light chain variable region (VL) are SEQ ID NOs: 10, 12, and 14, respectively.
1. An antibody, or a fragment thereof, capable of immunologically and specifically binding to a folate receptor α and a folate receptor β, in which the amino acid sequences of CDRH1, CDRH2, and CDRH3 of a heavy chain variable region (VH) are the amino acid sequences of SEQ ID NOs: 2, 4, and 6, respectively, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of a light chain variable region (VL) are the amino acid sequences of SEQ ID NOs: 10, 12, and 14, respectively.
2. The antibody according to claim 1 , wherein the antibody is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a single chain antibody, and a multispecific antibody.
3. The antibody according to claim 1 , which is a human antibody or a humanized antibody.
4. A molecular-targeted anticancer agent, comprising a drug bound to the antibody of claim 1 .
5. The molecular-targeted anticancer agent according to claim 4 , wherein the drug is selected from the group consisting of a toxin, a cytotoxic agent, an enzyme, a cytokine, and a chemotherapeutic agent.
6. The molecular-targeted anticancer agent according to claim 5 , wherein the toxin is a bacterium-derived toxin.
7. The molecular-targeted anticancer agent according to claim 6 , wherein the bacterium-derived toxin is Pseudomonas toxin, diphtheria toxin, or staphylococcal toxin.
8. The molecular-targeted anticancer agent according to claim 5 , wherein the cytotoxic agent is selected from the group consisting of an antitumor agent, a tumor growth inhibitor, a tumor cell apoptosis inducer, and a radioactive nuclide.
9. The molecular-targeted anticancer agent according to claim 4 , wherein the molecular-targeted anticancer agent is an immunotoxin.
10. A pharmaceutical composition for cancer treatment, which comprises the molecular-targeted anticancer agent according to claim 4 , and a pharmaceutically acceptable carrier.
11. A cancer diagnostic agent, which is obtained by binding a label to the antibody according to claim 1 .
12. The cancer diagnostic agent according to claim 11 , wherein the label is a fluorophore, a pigment, or a radioactive isotope.
13. The antibody of claim 1 , that is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, a chimeric antibody, and a multispecific antibody.
14. The antibody of claim 1 , that is a monoclonal antibody.
15. An antibody capable of immunologically and specifically binding to a folate receptor α and a folate receptor β, in which the amino acid sequences of CDRH1, CDRH2, and CDRH3 of a heavy chain variable region (VH) are the amino acid sequences of SEQ ID NOs: 2, 4, and 6, respectively, and the amino acid sequences of CDRL1, CDRL2, and CDRL3 of a light chain variable region (VL) are the amino acid sequences of SEQ ID NOs: 10, 12, and 14, respectively.